Reversal of Acute Cellular Rejection After Renal Transplantation With Campath-1H

Basu, Amit; Ramkumar, M.; Tan, Henkie P.; Khan, Rafeeq Alam; McCauley, Jerry; Marcos, Amadeo; Fung, John J.; Starzl, Thomas E.; Shapiro, Ron

doi:10.1016/j.transproceed.2004.12.019

Cited by 52 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…177 Treatment of rejection appears similarly effective in kidney transplant recipients but may be associated with increased early infection-related deaths. 85,109,115,[178][179][180] Woodside and Lick 181 described successful reversal of cardiac rejection in a patient with recurrent and refractory hemodynamically significant rejection. To date, there are no studies evaluating alemtuzumab as treatment for rejection in heart transplantation.…”

Section: Alemtuzumab (Campath)mentioning

confidence: 99%

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Colvin¹,

Cook²,

Chang³

et al. 2015

Circulation

282

251

View full text Add to dashboard Cite

Section: Alemtuzumab (Campath)mentioning

confidence: 99%

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Colvin¹,

Cook²,

Chang³

et al. 2015

Circulation

282

251

View full text Add to dashboard Cite

“…The frequency of nocardial infections in solid organ transplant recipients varies between 0.7% and 3.5%, and in the past these infections were mostly reported in heart, kidney and liver transplant recipients, and less frequently in lung transplantation (11)(12)(13) (19). Although nocardial infection in transplant recipients usually develops within the first year posttransplant (13,20) (29). It causes profound lymphopenia and its use in the setting of rejection has been associated with a number of opportunistic infections including nocardiosis (30).…”

Section: They Are Part Of a Heterogeneous Subgroup Of Gram-positivementioning

confidence: 99%

Nocardia in Solid Organ Transplant Recipients

Clark

2009

American Journal of Transplantation

View full text Add to dashboard Cite

“…Alemtuzumab is currently registered for the treatment of chronic lymphatic leukemia but data on the safety and efficacy of treatment of acute rejection after organ transplantation are scarce. Several studies reported the results in small groups of patients, merely demonstrating that recurrent or steroid-resistant rejection can be reversed with alemtuzumab (6)(7)(8)(9)(10). Randomized trials comparing alemtuzumab with other T cell-depleting agents for the treatment of acute rejection have not been performed.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Steroid-Resistant Acute Renal Allograft Rejection With Alemtuzumab

Hoogen

Hesselink

Son

et al. 2013

American Journal of Transplantation

View full text Add to dashboard Cite

Steroid-resistant renal allograft rejections are commonly treated with rabbit antithymocyte globulin (RATG), but alemtuzumab could be an effective, safe and more convenient alternative. Adult patients with steroid-resistant renal allograft rejection treated with alemtuzumab (15-30 mg s.c. on 2 subsequent days) from 2008 to 2012 (n = 11) were compared to patients treated with RATG (2.5-4.0 mg/kg bodyweight i.v. for 10-14 days; n = 20). We assessed treatmentfailure (graft loss, lack of improvement of graft function or need for additional anti-rejection treatment), infections during the first 3 months after treatment and infusion-related side effects. In both groups, the median time-interval between rejection and transplantation was 2 weeks, and approximately 75% of rejections were classified as Banff-IIA or higher. Three alemtuzumab-treated patients (27%) experienced treatment failure, compared to eight RATG treated patients (40%, p = 0.70). There was no difference in the incidence of infections. There were mild infusion-related side-effects in three alemtuzumabtreated patients (27%), and more severe infusionrelated side effects in 17 RATG-treated patients (85%, p = 0.013). Drug related costs of alemtuzumabtreatment were lower than of RATG-treatment (€1050 vs. €2024; p < 0.01). Alemtuzumab might be an effective therapy for steroid-resistant renal allograft rejections. In contrast to RATG, alemtuzumab is nearly devoid of infusion-related side-effects. These data warrant a prospective trial.

show abstract

Reversal of Acute Cellular Rejection After Renal Transplantation With Campath-1H

Cited by 52 publications

References 12 publications

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Nocardia in Solid Organ Transplant Recipients

Treatment of Steroid-Resistant Acute Renal Allograft Rejection With Alemtuzumab

Contact Info

Product

Resources

About